Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
59.35
-0.24 (-0.40%)
Oct 14, 2025, 8:21 AM EDT - Market open
Cytokinetics Stock Forecast
Stock Price Forecast
The 15 analysts that cover Cytokinetics stock have a consensus rating of "Buy" and an average price target of $76.73, which forecasts a 29.28% increase in the stock price over the next year. The lowest target is $41 and the highest is $120.
Price Target: $76.73 (+29.28%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 4 | 4 | 5 | 5 |
| Buy | 7 | 7 | 7 | 7 | 9 | 9 |
| Hold | 3 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 14 | 14 | 14 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $71 → $82 | Buy | Maintains | $71 → $82 | +38.16% | Oct 6, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $52 → $56 | Hold | Maintains | $52 → $56 | -5.64% | Oct 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +102.19% | Sep 29, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $74 → $80 | Strong Buy | Maintains | $74 → $80 | +34.79% | Sep 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +102.19% | Sep 22, 2025 |
Financial Forecast
Revenue This Year
85.65M
from 18.47M
Increased by 363.61%
Revenue Next Year
140.53M
from 85.65M
Increased by 64.08%
EPS This Year
-5.73
from -5.26
EPS Next Year
-5.80
from -5.73
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 161.5M | 245.7M | |||
| Avg | 85.6M | 140.5M | |||
| Low | 66.6M | 49.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 774.3% | 186.9% | |||
| Avg | 363.6% | 64.1% | |||
| Low | 260.7% | -42.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.20 | -4.29 | |||
| Avg | -5.73 | -5.80 | |||
| Low | -6.19 | -7.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.